Equities

Rekah Pharmaceutical Industry Ltd.

REKA:TLV

Rekah Pharmaceutical Industry Ltd.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ILa)1,204.00
  • Today's Change-21.00 / -1.71%
  • Shares traded390.00
  • 1 Year change-24.80%
  • Beta0.1178
Data delayed at least 20 minutes, as of Jun 06 2024 15:24 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rekah Pharmaceutical Industry Ltd. (Rekah) is an Israel-based company which operates directly and through its subsidiaries. The Company operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The Company distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.

  • Revenue in ILS (TTM)332.33m
  • Net income in ILS-6.29m
  • Incorporated1993
  • Employees434.00
  • Location
    Rekah Pharmaceutical Industry Ltd.30 Hamelach StreetHOLON 5881904IsraelISR
  • Phone+972 35581233
  • Fax+972 35565919
  • Websitehttps://www.rekah.co.il/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Liberta Co Ltd177.49m-169.14k90.71m118.00--2.6026.070.5110-2.34-2.342,487.28482.671.202.677.6562,643,520.00-0.10683.75-0.21696.4238.2441.81-0.08912.370.82473.150.694835.676.779.76-2.77-12.8523.12--
Delko SA857.70m15.92m93.17m1.16k5.850.63032.980.10861.401.4075.4813.012.650.168011.04--4.93--8.46--98.30--1.86--0.7361849.720.3958--------------
Rhone Ma Holdings Bhd164.10m9.69m114.47m--16.090.87588.230.69750.04040.04040.68420.74220.94242.934.98--6.266.157.477.3826.4028.116.646.852.9113.360.14432.112.418.46-5.163.72-27.03-7.79
EZZ Life Science Holdings Ltd108.88m8.65m114.50m--12.712.8912.131.050.08140.08141.020.35822.489.6313.51--19.6921.2224.8529.1974.7755.317.949.113.61293.270.019513.08147.26--176.57------
Penta Valent Tbk PT610.69m9.37m130.65m--13.792.3412.220.213923.3623.361,525.15137.393.068.956.37--4.69--15.53--12.01--1.54--0.925811.070.2678--15.71--53.62------
Microalliance Group Inc85.51m36.68m136.83m30.004.441.203.681.600.01350.01350.03250.05010.76310.486912.65762,790.3032.74--35.89--68.46--42.90--12.67--0.00--3,030.68--3,074.43------
Rekah Pharmaceutical Industry Ltd332.33m-6.29m142.09m434.00--0.90495.740.4276-0.5667-0.566730.7913.630.71532.652.53---1.350.543-1.960.736424.9226.41-1.890.83670.99390.22710.5251--10.0110.13-238.56---4.89--
COSMO BIO COMPANY, LIMITED227.03m9.80m146.24m155.0014.400.6610.720.644169.9469.941,620.671,525.810.84846.092.8761,000,000.003.805.624.546.7233.8237.404.486.235.15--0.002133.53-2.235.16-14.5111.20-8.0316.47
McPherson's Ltd502.36m-8.87m159.56m876.00--0.585227.420.3176-0.0248-0.02481.400.76040.99072.095.72---1.751.04-2.561.5050.1546.06-1.770.91520.91032.820.1822409.37-1.79-0.0665-1,619.82--0.3719-18.80
Kingworld Medicines Group Ltd557.26m19.68m166.80m1.00k8.050.52163.950.29930.06960.06961.971.070.82947.8913.471,162,350.004.744.078.578.0026.0229.725.715.591.02--0.336341.8312.63-0.003467.52-1.4654.829.24
Able View Global Inc556.75m35.28m176.83m98.005.074.194.900.31760.22290.22293.520.26952.726.208.371,520,406.0017.80--30.88--24.84--6.54--1.997.900.2017--2.58--23.46------
Data as of Jun 06 2024. Currency figures normalised to Rekah Pharmaceutical Industry Ltd.'s reporting currency: Israeli Shekel ILS

Institutional shareholders

1.70%Per cent of shares held by top holders
HolderShares% Held
Yelin Lapidot Mutual Fund Management Ltd.as of 29 Feb 2024157.22k1.36%
IBI Mutual Funds Management (1978) Ltd.as of 29 Feb 202421.53k0.19%
Excellence Nessuah Mutual Funds Management Ltd.as of 29 Feb 202414.02k0.12%
Meitav Mutual Funds Ltd.as of 29 Feb 20241.73k0.02%
KSM Mutual Funds Ltd.as of 29 Feb 20241.10k0.01%
Migdal Mutual Funds Ltd.as of 29 Feb 2024523.000.01%
Psagot Mutual Funds Ltd.as of 29 Feb 2024130.000.00%
Harel Mutual Funds Ltd.as of 29 Feb 202445.000.00%
More ▼
Data from 29 Feb 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.